Abstract:Objectives Tissue inhibitor of metalloproteinases-1 (TIMP-1) is considered to play a key role in the development of pulmonary arterial hypertension (PAH). However, the molecular regulatory mechanisms of TIMP-1 in the pulmonary arteries were not very clear, especially in the human pulmonary arterial smooth muscle cells (HPASMCs). This study try to investigate the signalling pathway involved in the regulation of TIMP-1 in HPASMCs stimulated with transforming growth factor (TGF)-β1. Methods Cultured HPASMCs were incubated with different concentrations of TGF-β1 (0, 2.5, 5, 10, 20 or 40 ng/ml) for 24 h, or with 10 ng/ml TGF-β1 for different time (1, 4, 8, 12, 24 or 48 h). Western blot and real-time PCR were employed to detect the protein and mRNA expression of TIMP-1 in HPASMCs, and enzyme-linked immuno sorbent assay (ELISA) was used to detect the secretion of TIMP-1 in the culture medium. Then, the activities of three mitogen-activated protein kinases (MAPK), including extracellular signal-regulated kinase 1/2 (ERK1/2), p38 and c-Jun NH2-terminal kinase (JNK), were respectively inhibited with their specific inhibitors, U0126, SB202190 and SP600125. The protein and mRNA of TIMP-1 were also detected to help distinguishing that which kinase was involved in the regulation of TIMP-1 in HPASMCs induced by TGF-β1. Besides this, mithramycin, a specific inhibitor of Sp1 transcription factor, and curcumin, a specific inhibitor of activator protein-1 (AP-1), were used to block the DNA-binding activity of Sp1 or AP-1 respectively. And electrophoretic mobility shift assay (EMSA), Western blot and real-time PCR were carried out to help confirming that which transcription factor was involved in the regulation of TIMP-1 in HPASMCs. Results Western blot, real-time PCR and ELISA analysis showed that TGF-β1 could time- and dose-dependently enhance the expression and secretion of TIMP-1. Furthermore, TGF-β1 could phosphorylate two kinases of MAPK, ERK1/2 and p38, but not JNK, and the phosphorylation of p38 was weaker compared with ERK1/2. Of these kinases, only the inhibition of ERK 1/2 by U0126 effectively blocked the TGF-β1-induced expression of TIMP-1. Mithramycin also significantly reduced the expression of TIMP-1 via blocking the DNA-binding activity of Sp1. However, the inhibition of AP-1 by curcumin couldn't achieve this result. Additionally, the results of EMSA showed that TGF-β1 could up-regulate the DNA-binding activity of Sp1, and that U0126 and mithramycin could effectively suppressed this activation in a dose-dependent manner. Conclusions TGF-β1 could time- and dose-dependently stimulate the expression and secretion of TIMP-1 in HPASMCs, and ERK1/2 and Sp1 signalling pathways might be involved in these activities.

Suppression of Tissue Inhibitors of Metalloproteinases May Reverse Severe Pulmonary Arterial Hypertension.

Epigenetic Regulation of Pulmonary Arterial Hypertension

ACTIVATION OF ERK 1/2 AND SP1 MAY CONTRIBUTE TO THE EXPRESSION OF TISSUE INHIBITOR OF METALLOPROTEINASE-1 INDUCED BY TRANSFORMING GROWTH FACTOR-β1 IN HUMAN PULMONARY ARTERIAL SMOOTH MUSCLE CELLS

Endothelial Progenitor Cells May Inhibit Apoptosis of Pulmonary Microvascular Endothelial Cells: New Insights into Cell Therapy for Pulmonary Arterial Hypertension

BMP9 attenuates IL-33 signaling and prevents endothelial-to-mesenchymal transition in pulmonary arterial hypertension

Crocin's role in modulating MMP2/TIMP1 and mitigating hypoxia-induced pulmonary hypertension in mice

Attenuating Pulmonary Hypertension by Protecting the Integrity of Glycocalyx in Rats Model of Pulmonary Artery Hypertension

The Impact of Highly Selective Thoracic Sympathectomy on the Progression of Monocrotaline-induced Pulmonary Arterial Hypertension in Rats

PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension

Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension.

Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1<alpha> signaling pathway.

Paeoniflorin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing TAK1-MAPK/NF-kappa B pathways

MED1 Regulates BMP/TGF-β in Endothelium: Implication for Pulmonary Hypertension

ERK/Drp1‐dependent mitochondrial fission contributes to HMGB1‐induced autophagy in pulmonary arterial hypertension

MnTBAP Reverses Pulmonary Vascular Remodeling and Improves Cardiac Function in Experimentally Induced Pulmonary Arterial Hypertension.

Paeoniflorin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing TAK1-MAPK/NF-κB pathways

Mutual inhibitory mechanisms between PPARγ and Hif-1α: implication in pulmonary hypertension.

Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs

Exacerbated inflammatory signaling underlies aberrant response to BMP9 in pulmonary arterial hypertension lung endothelial cells

Suppression of Aseptic Inflammation Reduces the Severity of Pulmonary Artery Remodeling and Improves the Clinical Course of Experimental Chronic Thromboembolic Pulmonary Hypertension